Safety of long-acting β-agonists in asthma: A review

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 1, 2008, Pages 64-69

  Oppenheimer, John ^a   Nelson, Harold S ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Asthma; Long acting 2 agonist; Safety

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; PLACEBO; SALMETEROL; STEROID; TRIAMCINALONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; MORTALITY; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AFRICAN AMERICANS; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY MUCOSA;

EID: 36548999382     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282f1980b     Document Type: Review

References (41)

1. Finkelstein FN. Risks of salmeterol? N Engl J Med 1994; 331:1314.
2. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial (SMART): a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26. This article is in large part the catalyst for the black-box warning regarding LABAs. The study was designed to assess the safety of added salmeterol in approximately 60 000 subjects with a history of asthma who had no prior exposure to a LABA in a real-world setting. Investigators obtained only minimal baseline demographics with no monitoring of symptoms, or pulmonary function and no measure of compliance with controller medicine(s). Intervention included the subject being provided with 7 months of study medicine (salmeterol or placebo) and a monthly telephone call to determine whether the subject was still taking the study medication, had made any other changes in asthma medication and whether they he/she experienced a life-threatening asthma episode. Enrollment in this study was terminated following a planned interim analysis that demonstrated an increase in mortality, especially in the African American subjects.
3. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904-912.
4. Martinez F. Safety of long-acting beta-agonists: an urgent need to clear the air. N Engl J Med 2005; 353:2637-2639.
5. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Publication no. 02-5074. Bethesda, Maryland: National Institutes of Health; 2002.
6. Anon. Global strategy for asthma management and prevention. Publication no. 02-3659. Bethesda, Maryland: National Institutes of Health; 2006.
7. Li J, Oppenheimer J, Bernstein IL, et al. Attaining asthma control. A practice parameter. J Allergy Clin Immunol 2005; 115:S3-S11.
8. Nelson HS. Is there a problem with inhaled long-acting β-adrenergic agonists? J Allergy Clin Immunol 2006; 117:3-16.
9. Ramage BJ, Lipworth CG, Ingram IA, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88:363-368.
10. Lipworth B, Tan S, Devlin M, et al. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998; 104:431-438.
11. O'Byrne PM, Barnes PJ, Rodriquez-Rotsin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1192-1197.
12. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-1373.
13. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60:730-734.
14. Greenstone IR, Ni Chromin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; CD005533.
15. Busse W, Koenig SM, Oppenheimer J, et al. Steroid sparing effects of fluticasone 100 mg and salmeterol 50 mg administered twice daily in a single product in patients previously controlled with fluticasone 250 mg twice daily. J Allergy Clin Immunol 2003; 111:57-65.
16. Wallin A, Sandstrom T, Soderberg M, et al. The effect of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159:79-86.
17. Maneechotesutwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005; 128:1936-1942.
18. Roberts JA, Bradding P, Britten KM, et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14:275-282.
19. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274:1005-1010.
20. Koopmans JG, Lutter R, Jansen HM, van der Zee JS. Adding salmeterol to inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 2006; 61:306-312.
21. Overbeek S, Mulder PG, Baelemans SM. Formoterol added to low-dose budesonide has no additional anti-inflammatory effect in asthmatic patients. Chest 2005; 128:1121-1127.
22. Jarjour NN, Wilson SJ, Koenig SM, et al. Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/ salmeterol. J Allergy Clin Immunol 2006; 118:44-52.
23. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting B2-agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285:2583-2593.
24. Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol; a randomized controlled trial. JAMA 2001; 285:2594-2603.
25. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924-930.
26. Pauwels R, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET). N Engl J Med 1998; 338:1405-1411.
27. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma. A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160:594-599.
28. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-1037.
29. Nelson HS, Dorinsky PM. Safety of long-acting β-agonist. Ann Intern Med 2006; 145:706.
30. Ernst P, McIvor A, Ducharne FM, et al. Safety and effectiveness of long-acting inhaled-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006; 145:692-694.
31. Nelson HS, Beasley R, Yancey SW, et al. No increase in asthma-related hospitalizations following the addition of salmeterol to an inhaled corticosteroid in patients with asthma: a meta-analysis. Am J Respir Crit Care Med 2007; 175:A59.
32. O'Brien CD, Peters SP, Prenner BM, Martin P. Long-term safety of budesonide/ formoterol pressurized metered-dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations. Am J Respir Crit Care Med 2007; 175:A188.
33. Kobilka BK, Dixon RA, Fielle HG, et al. cDNA for the human B2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoding by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987; 84:46-50.
34. Green SA, Turki J, Hall IP, Ligget SB. Implications of genetic variability of human B2-adrenergic receptor structure. Pulmon Pharmacol 1995; 8:1-10.
35. Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta 2-adrenoreceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-3188.
36. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80.
37. Israel E, Chinchillli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
38. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term agonist use: influence of β2 adrenoceptor polymorphism. Thorax 2000; 55:762-767.
39. Weschsler ME, Lehman E, Lazarus SC, et al. B-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
40. Bleecker ER, Yancey SW, Baitinger LA. Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-816.
41. 2-adrenergic receptor variation on the long-term safety of formoterol in combination with budesonide and budesonide alone delivered via one pressurized metered-dose inhaled in patients with moderate to severe asthma. Am J Respir Crit Care Med 2007; 175:A59.